Therapy Name | ABT-700 |
Therapy Description |
ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABT-700 | h224G11 | MET Antibody 12 | ABT-700 (h224G11) is a monoclonal antibody that targets and inhibits c-MET (PMID: 23134362). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | MET amp | Advanced Solid Tumor | sensitive | ABT-700 | Phase I | Actionable | In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)). | detail... |
---|